Scaffolds are used broadly in tissue engineering and regenerative biology research, and not all of them are tissue-derived; some are synthetic. What they share is a structural role, providing a framework rather than functioning primarily through living cell activity.
This terminology is relevant to Wharton's jelly products: a 2026 composition study of six commercial cord allografts reported low total cell counts and low cell viability, with only rare viable mesenchymal stromal cells identified. Those findings are specific to the products studied; confirm composition and viability data for any specific lot rather than assuming it applies broadly. Reviewing the certificate of analysis for that lot clarifies whether it is being described in terms of matrix content, cellular content, or both.
Ask any supplier whether a product is being positioned as a scaffold or matrix material versus a cellular product, and request whatever composition and viability data appears in the certificate of analysis for the specific lot. How a scaffold-type allograft's intended use maps to the applicable regulatory framework is a determination for the clinic and its own counsel.
Distinguishing "scaffold" from "cell therapy" terminology helps buyers evaluate matrix-based allografts accurately and ask for the right composition documentation.